OPHLY लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (29 Jun 2024 @ 01:23):
No signals from the correlation tool

Stats
आज की मात्रा	11 146
औसत मात्रा	164 619
बाजार मूल्य	6.41B
EPS	$37.54 ( Q4 \| 2024-03-31 )
अगली कमाई की तारीख	( $0 ) 2024-07-30
Last Dividend	$0.0823 ( 2021-09-28 )
Next Dividend	$0 ( N/A )
P/E	8.12 (Sector) 0 (Industry) 0
ATR14	$0.00700 (0.15%)

ALPMY -1.01%

BAYRY 0.86%

CHGCY -1.99%

DSKYF 0.00%

DSNKY 0.82%

GIKLY 0.00%

HAWPY -6.10%

OPHLF -3.35%

OPHLY -0.87%

ORINY 0.00%

OTSKY 1.24%

RHHBY -0.74%

SNPHF 0.00%

SNPHY 0.00%

सहसंबंध (AI algo v.1.1b): Paired value (एल्गो वास्तविक समय में सबसे अधिक सहसंबंधित स्टॉक्स के परिवर्तनों का ट्रैक करता है और तत्काल अद्यतन देता है)

मात्रा सहसंबंध

लंबा: -0.01 (neutral)

छोटा: 0.32 (neutral)

Signal:(56.923) Neutral

Ono Pharmaceutical Co., सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Ono Pharmaceutical Co., सहसंबंध - मुद्रा/वस्त्र

0.72
( moderate )

-0.40
( neutral )

0.00
( neutral )

-0.64
( weak negative )

Ono Pharmaceutical Co., वित्तीय

Annual	2024
राजस्व:	$502.67B
सकल लाभ:	$375.55B (74.71 %)
EPS:	$266.61

FY	2024
राजस्व:	$502.67B
सकल लाभ:	$375.55B (74.71 %)
EPS:	$266.61

FY	2023
राजस्व:	$447.19B
सकल लाभ:	$337.13B (75.39 %)
EPS:	$230.85

FY	2022
राजस्व:	$361.36B
सकल लाभ:	$267.85B (74.12 %)
EPS:	$162.19

Financial Reports:

No articles found.

Ono Pharmaceutical Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Ono Pharmaceutical Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 6.18 - Stable (23.67%)

Information

First Dividend	$0.0831	2021-03-29
Last Dividend	$0.0823	2021-09-28
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$0.165	--
Avg. Dividend % Per Year	0.00%	--
Score	3.8	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	6.18
Div. Directional Score	9.26	--

Next Divdend (Est)
(2024-12-19)

$0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

3.80

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Dividend History

Ex Date	Amount	Declaration Date	Record Date	Payment Date
28 Sep 2021	$0.0823	30 Nov -0001	30 Nov -0001	30 Nov -0001
29 Mar 2021	$0.0831	30 Nov -0001	30 Nov -0001	30 Nov -0001

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
LTOUF	Ex Dividend Junior	2023-08-01	Annually	0.00%
AILLO	Ex Dividend Knight	2023-07-14	Semi-Annually	0.00%
YZCAY	Ex Dividend Junior	2023-07-03	Annually	0.00%
HEGIY	Ex Dividend Knight	2023-09-15	Semi-Annually	0.00%
SPKKY	Ex Dividend Knight	2023-09-14	Annually	0.00%
CYFL	Ex Dividend Knight	2023-09-05	Quarterly	0.00%
NODB	Ex Dividend Junior	2023-10-17	Quarterly	0.00%
BDVSY	Ex Dividend Junior	2023-09-28	Annually	0.00%
IVSBF	Ex Dividend Knight	2023-11-03	Annually	0.00%
UEPCP	Ex Dividend Knight	2023-07-20	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.255	1.500	4.91	7.36	[0 - 0.5]
returnOnAssetsTTM	0.140	1.200	5.33	6.40	[0 - 0.3]
returnOnEquityTTM	0.164	1.500	9.29	10.00	[0.1 - 1]
payoutRatioTTM	0.291	-1.000	7.09	-7.09	[0 - 1]
currentRatioTTM	3.99	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	3.29	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.603	1.500	2.20	3.31	[0.2 - 2]
debtRatioTTM	0.00970	-1.500	9.84	-10.00	[0 - 0.6]
interestCoverageTTM	119.29	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	234.16	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	190.09	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.0112	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.747	1.000	0.882	0.882	[0.2 - 0.8]
operatingProfitMarginTTM	0.324	1.000	5.51	5.51	[0.1 - 0.6]
cashFlowToDebtRatioTTM	12.49	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.550	0.800	9.67	7.73	[0.5 - 2]
Total Score				12.33

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	2.70	1.000	9.83	0	[1 - 100]
returnOnEquityTTM	0.164	2.50	9.54	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	190.09	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.0124	1.500	9.69	0	[0 - 0.4]
operatingCashFlowPerShareTTM	234.16	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.291	1.500	7.09	-7.09	[0 - 1]
pegRatioTTM	0.00114	1.500	-3.33	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.220	1.000	7.00	0	[0.1 - 0.5]
Total Score				6.18

Ono Pharmaceutical Co., Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Ono Pharmaceutical Co.,

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.